Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial - Concepedia

Concepedia

Publication | Closed Access

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

163

Citations

27

References

2014

Year

Jacob A. Udell, Deepak L. Bhatt, Eugene Braunwald, Matthew A. Cavender, Ofri Mosenzon, Philippe Gabríel Steg, Jaime A. Davidson, José Carlos Nicolau, Ramón Corbalán, Boaz Hirshberg,

Abstract

Saxagliptin did not affect the risk of ischemic cardiovascular events, increased the risk of heart failure hospitalization, and reduced progressive albuminuria, irrespective of baseline renal function.

References

	Year	Citations

Page 1